FindTrial
Sign In

An exploratory research on the influence of amyloid deposit (measured with (18F)flutemetamol) on disconnection in the “core episodic network” and between regions involved in anosognosia for memory impairment

An exploratory research on the influence of amyloid deposit (measured with (18F)flutemetamol) on disconnection in the “core episodic network” and between regions involved in anosognosia for memory impairment

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2012-004462-18-BE
Enrollment
60
Registered
2012-11-09
Start date
2013-04-23
Completion date
Unknown
Last updated
2023-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease (mild, moderate and moderately severe stage) and control population

Interventions

Product Name: [18F] flutemetamol Pharmaceutical Form: Solution for injection INN or Proposed INN: [18F] flutemetamol CAS Number: 765922-62-1 Other descriptive name: Flutemetamol F-18

Sponsors

Service of Neurology CHU Liege
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Control population without major disease and with normal cognition. Alzheimer's disease diagnosed according to international criteria. Age between 50 and 90 y Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 10 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 50

Exclusion criteria

Exclusion criteria: Exclusion criteria will be systemic disease, cancer, associated vascular dementia. Exclusion criteria for MRI will be taken into account.

Design outcomes

Primary

MeasureTime frame
Main Objective: Search for the effect of amyloid deposit on brain disconnection and anosognosia for memory impairment in Alzheimer's disease;Secondary Objective: Search for influence of amyloid deposit on Magnetic Resonance Imaging measured brain regional activity disconnection;Primary end point(s): No defined end points Pathophysiological research;Timepoint(s) of evaluation of this end point: Not applicable—

Secondary

MeasureTime frame
Secondary end point(s): Not applicable;Timepoint(s) of evaluation of this end point: NA—

Countries

Belgium

Contacts

Public ContactSalmon

CHU Liege / ULG

eric.salmon@ulg.ac.be

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026